Noopept vs Semax: Which Is Better for Cognition and Focus?
Should I take noopept or semax for focus and memory?
Semax scores 7.1/10 against noopept's 6.2/10 and wins five of the eight use cases both reports score. Noopept is oral, cheaper at $5 to $27 a month, and takes the anxiety row. Semax has the stronger human record. If you have high blood pressure, noopept is the one to skip.
- Semax 7.1/10 in the strong recommend tier, noopept 6.2/10 in the worth trying tier. Both are Russian, both are unapproved in the US, and neither has ever been tested against a placebo.
- Semax takes cognition focus 6.5/10 to 5.5/10, memory 6.0/10 to 5.5/10, neuroplasticity 6.0/10 to 4.5/10, neuroprotection 6.5/10 to 5.0/10 and stress resilience 4.0/10 to 3.0/10. Noopept takes anxiety 4.0/10 to 3.5/10. Mood and geriatric are exact ties at 3.5/10 and 5.0/10.
- Noopept is cheaper and easier: $5 to $27 a month for a capsule you swallow, against an estimated $12 to $60 for a nasal spray.
- Blood pressure is the one hard split. A rise in a minority of users is noopept's only reproducible objective finding, and the manufacturer warns against combining it with antihypertensives.
- Both feel like something inside an hour, and that is where the clocks separate: semax is judged at 2 weeks, noopept at 8.
- I've run both. Semax several times a month for years, noopept on and off since 2014. I rate semax 6.5 and noopept 6.1.
At a Glance
Noopept (Omberacetam)
- Efficacy Moderate
- Breadth Moderate
- Evidence Moderate
- Speed Strong
- Durability Limited
- Bioindividuality Moderate
- Safety Risk Low
- Side Effects Low
- Cost premium Low
- Effort Low
- Opportunity Cost Low
- Dependency Low
- Reversibility Negligible
- Cognition & Focus
- Memory
- Neuroprotection
- Geriatric & Aging
Oral synthetic dipeptide, 10 mg twice daily, sold over the counter in Russia. BioHarmony 6.0–6.5/10, worth trying.
Semax
- Efficacy Strong
- Breadth Strong
- Evidence Strong
- Speed Strong
- Durability Moderate
- Bioindividuality Moderate
- Safety Risk Low
- Side Effects Low
- Cost premium Low
- Effort Low
- Opportunity Cost Low
- Dependency Low
- Reversibility Negligible
- Cognition & Focus
- Neuroprotection
- Memory
- Neuroplasticity
Russian ACTH 4-7 plus PGP heptapeptide, usually a nasal spray. BioHarmony 7.0–7.5/10, strong recommend.
Head-to-Head Verdict
| Use Case | Winner | Rationale |
|---|---|---|
| Cognition & Focus | Semax | Semax 6.5/10 against noopept 5.5/10, and the split is about who was studied. Semax has Russian attention and operative-memory work in people who were not impaired (Asmarin 1997, Kaplan 1996). Noopept's only human cognition endpoint is MMSE in vascular and post-stroke patients (Amelin 2011), a real signal measured in the wrong population for most readers. |
| Memory | Semax | Semax 6.0/10 against noopept 5.5/10, the narrowest scored row here. Noopept's memory case is human but blunt: MMSE is a 30-point screening test, not a memory battery, and both trials were unblinded. Semax carries a human memory signal from 1996 plus rat hippocampal work (Dolotov 2006, Ellis 2020). Two thin records, and semax's covers healthy adults as well as patients. |
| Neuroplasticity | Semax | Semax 6.0/10 against noopept 4.5/10. Both rest on rodent neurotrophic data: noopept raises hippocampal NGF and BDNF (Ostrovskaya 2008), semax raises BDNF and TrkB after intranasal dosing (Dolotov 2006). Semax wins because one human study measured the marker, with plasma BDNF rising in 110 post-stroke patients (Gusev 2018). No noopept study has. |
| Neuroprotection | Semax | Semax 6.5/10 against noopept 5.0/10, the widest gap here. Noopept has the more detailed mechanism, cutting reactive oxygen species, calcium overload and tau phosphorylation in an Alzheimer cell model (Ostrovskaya 2014). Semax has the human end of the same story: 110 post-stroke patients with BDNF and rehabilitation outcomes (Gusev 2018). A dish against a ward. |
| Anxiety | Noopept (Omberacetam) | Noopept 4.0/10 against semax 3.5/10, the one row noopept takes. Anxiolytic effects run consistently through noopept's animal pharmacology (Ostrovskaya 2002) and a subset of users describe the same thing. Neither compound has a human anxiety scale behind it, so this is a comparison of two unmeasured claims where noopept's animal record is the more consistent of the two. Treat it as a lean, not a finding. |
| Mood & Emotion | Tie | An exact tie at 3.5/10 each, and both scores sit that low for the same reason. Mood shows up as a secondary observation in noopept's human record rather than a measured endpoint, and a distinct minority of users report the opposite effect, a flattening of affect that does not always lift while dosing continues. Semax has no dedicated mood trial either. Neither is a mood intervention. |
| Geriatric & Aging | Tie | An exact tie at 5.0/10, and this is the only population either compound was properly studied in. Amelin 2011 enrolled 60 stroke patients on noopept and described a high level of safety; Gusev 2018 enrolled 110 on semax. The tiebreak cuts both ways: noopept's blood-pressure signal matters more in a cohort already on antihypertensives, and semax costs more. |
| Stress & Resilience | Semax | Semax 4.0/10 against noopept 3.0/10, and both numbers describe inference rather than measurement. Semax has one animal result pointed at the question: Ellis 2020 found episodic memory protected in hypoxia-exposed rats, which is a stressor model. Noopept's resilience case is read across from its anxiolytic animal work. No human cortisol, HRV or burnout endpoint exists for either compound. |
Cost Comparison
| Intervention | Monthly Cost | Notes |
|---|---|---|
| Noopept | $5 to $27 | Priced 2026-09-09, research-chemical channel, at the studied 20 mg a day. Tested 20 mg capsules from a European vendor run roughly $25 to $27 a month at one capsule a day. Bulk raw powder runs under $5 a month for the same dose.The ten-fold gap is what verification costs. The cheap version is unweighed powder, and there is no lawful US retail channel at any price, so the vendor decision matters more than the sticker. |
| Semax | $12 to $60 | Estimated, September 2026 prices, research-chemical channel, at 300 to 600 mcg a day of 0.1% spray. A pre-mixed 30 mg 0.1% nasal spray runs $40 to $100.At 300 mcg a day (9 mg a month) that is $12 to $30. At 600 mcg a day (18 mg a month) it is $24 to $60. These are estimated figures from typical vendor pricing rather than a measured receipt. |
| The difference | Noopept is cheaper at both ends of the range | At the floor it is $5 against $12. At the ceiling it is $27 against $60. Noopept is roughly half the price wherever you compare, and the semax figure is an estimate while the noopept figure comes from listed vendor prices.Neither number is large enough to decide this. A year of either sits under $750, so pick on the blood-pressure question, the evidence you want behind you, and whether you would rather swallow a capsule or spray your nose.Supply is the one moving part. Nootropics Depot has discontinued its noopept products and CosmicNootropic has moved its listing to a liquidation sale, so the tested-capsule end of the noopept market is thinner than it was, which pushes buyers toward the powder the purity data is worst for. |
When to Switch
These two run on different clocks, and that is the practical difference between them. Both give responders something inside about an hour, usually easier word retrieval and steadier attention.
After that they separate. Semax reaches full effect at 2 weeks with a 2-week assessment window. Noopept was studied in courses of 1.5 to 3 months and its measured cognitive result arrived at roughly 8 weeks. Semax fails fast. Noopept asks for a season.
Move from noopept to semax when your blood pressure runs high or you already take an antihypertensive, when the acute effect faded and you want the compound with the 110-patient trial behind it, or when a full 8-week noopept course measured nothing.
Move from semax to noopept when a nasal spray is the part you keep skipping, when you want a cheaper experiment you can run for two months, or when semax's cost or vendor situation stops being worth it. Neither move is an upgrade in evidence quality, because neither compound has faced a placebo.
Do not run them together. Both converge on NGF and BDNF signalling by different doors, so the combination is redundant rather than additive, it doubles the gray-market sourcing risk, and a benefit or a bad reaction could not be attributed to either one. Whichever you pick, write down the marker before you start, and if it is noopept, take a blood-pressure reading first.
Who Should Pick What?
Anyone with hypertension or taking an antihypertensive
Semax
Noopept is out, and this is the clearest call on the page. A rise in blood pressure is the one reproducible objective finding in noopept's human record, two people in the 56-day study reportedly needed treatment for it, and the manufacturer specifically warns against that drug combination. Semax carries no equivalent cardiovascular signal.
Experienced nootropic user who wants the strongest human record
Semax
Cognition focus 6.5/10 against 5.5/10, and Gusev 2018 studied 110 post-stroke patients with BDNF and rehabilitation outcomes. Semax also fails fast: a 2-week window at an estimated $12 to $30 means a wasted experiment costs you a fortnight. Noopept's studied course is 8 weeks.
Someone who wants the cheapest honest experiment
Noopept (Omberacetam)
$5 to $27 a month against an estimated $12 to $60, and it is a capsule you swallow rather than a spray you have to remember. Buy the tested capsule rather than bulk powder, because Cohen 2020 found 9 of 12 declared amounts in this category inaccurate, and take a blood-pressure reading before you start.
Older adult with vascular or post-stroke cognitive impairment, working with a clinician
Tie
Geriatric is an exact tie at 5.0/10 and this is the only population either compound was studied in: 60 stroke patients on noopept (Amelin 2011), 110 on semax (Gusev 2018). Both trials were unblinded. Bring both to the neurologist, and let the blood-pressure history decide, since that is where noopept's one objective risk lands.
Anyone prone to emotional blunting on serotonergic or dopaminergic drugs
Semax
Flattened affect, lost motivation and reduced libido are noopept's distinctive negative reports, and a subset describe them as not resolving while dosing continues. That is the reason its mood score is 3.5/10 and its libido score is 1.5/10. Semax's cautions run in a different direction: seizure history, high baseline anxiety and unstable psychiatric symptoms.
Pregnant, breastfeeding, or under 18
Tie
Neither, with no ambiguity. Pregnancy and breastfeeding are listed contraindications on both reports, and the Russian noopept label adds anyone under 18 plus severe hepatic or renal impairment. No prenatal or pediatric safety data exists for either compound, so there is nothing to weigh against.
Athlete competing under anti-doping rules
Tie
Neither, without formal sport-specific clearance, which in practice means not using them. Drug-tested sport eligibility is a listed contraindication on the semax side, and the WADA S0 category catches non-approved substances whether or not they are named. Noopept is an unapproved drug in the US on the same logic.
Research Highlights
-
Mechanism Difference
Noopept and semax reach the same destination through different doors. Noopept is an oral prodrug: esterases convert it to cycloprolylglycine, which raises hippocampal NGF and BDNF expression, modulates alpha-7 nicotinic receptors and activates HIF-1.Semax is an intranasal ACTH 4-7 fragment with a Pro-Gly-Pro tail, acting through BDNF and TrkB, NGF, cholinergic modulation and melanocortin activity. Both aim at neurotrophic signalling, which is why stacking them adds sourcing risk rather than mechanism.
-
Safety Comparison
Noopept scores 1.8/5 on safety risk and 2.1/5 on side effects; semax scores 1.8/5 and 1.8/5. The numbers are close and the risks are not the same shape. Noopept's is specific: blood pressure rose in a minority of trial participants, which is its only reproducible objective finding.Semax's cautions are seizure history, high baseline anxiety, unstable psychiatric symptoms and MAOI therapy. Both rule out pregnancy and breastfeeding. Noopept adds anyone under 18 and severe hepatic or renal impairment.
-
Cost Comparison
Noopept runs $5 to $27 a month at the studied 20 mg a day, priced 2026-09-09: roughly $25 to $27 for tested European capsules, under $5 for bulk powder. Semax is an estimated $12 to $60 a month at 300 to 600 mcg a day of 0.1% spray, priced 2026-09-07.Noopept is about half the price wherever you compare. Neither figure is large enough to decide the question, and the noopept market's tested end is contracting.
-
Access Risk
Both are gray market in the US and both fail the same way, through the bottle rather than the route. Noopept is an unapproved new drug named in a 2019 FDA warning letter, prohibited for human sale in the UK and controlled in Hungary.Semax is a research nasal spray with no product standard. Cohen 2020 found 9 of 12 declared amounts in this product category inaccurate, with exposure reaching four times pharmaceutical dosing, so verification is the buyer's job on both sides.
-
Evidence Quality
Confidence on this pair is low, and it is low for the same reason on both sides. Neither compound has ever been tested against a placebo, and each one's human record comes from a single country, largely a single institutional lineage.Noopept has two unblinded Russian trials, the stronger an open study of 60 stroke patients. Semax has Gusev 2018 in 110 post-stroke patients plus older attention work. No Western replication exists for either.
-
Editorial Verdict
Semax scores 7.1/10 in the strong recommend tier and noopept 6.2/10 in the worth trying tier, and semax takes five of the eight use cases both reports score. For a reader who wants the better human record and a verdict in two weeks, semax is the pick.Noopept earns its place on price, route and speed of trial rather than evidence. If your blood pressure runs high, skip noopept regardless of what the rest of the page says.
Frequently Asked Questions
- Is noopept or semax better?
- Semax, for most people. It scores 7.1/10 against noopept's 6.2/10 and takes five of the eight use cases both reports score: cognition focus 6.5/10 to 5.5/10, memory 6.0/10 to 5.5/10, neuroplasticity 6.0/10 to 4.5/10, neuroprotection 6.5/10 to 5.0/10 and stress resilience 4.0/10 to 3.0/10. Noopept takes anxiety 4.0/10 to 3.5/10, costs about half as much, and is a capsule rather than a spray.
- Which one has better evidence?
- Semax, narrowly, and neither is strong. Its best human study is Gusev 2018, 110 post-stroke patients showing raised plasma BDNF and better rehabilitation scores, plus attention work from the 1990s. Noopept has two unblinded Russian trials, the stronger an open study of 60 stroke patients at 20 mg daily. Neither compound has faced a placebo.
- How much does each one cost?
- Noopept runs $5 to $27 a month at the studied 20 mg a day, priced 2026-09-09: roughly $25 to $27 for tested European capsules, under $5 for bulk research-chemical powder. Semax is an estimated $12 to $60 a month at 300 to 600 mcg a day of 0.1% spray, priced 2026-09-07. Noopept is about half the price at both ends of the range.
- Does noopept raise blood pressure?
- In a minority of users, yes, and it is the clearest reason to pick semax instead. A blood-pressure rise is the one reproducible objective finding in noopept's human record, two people in the 56-day study reportedly needed treatment for it, and the manufacturer warns against combining it with antihypertensives. Take a reading before and during a course.
- How fast does each one work?
- Both give responders something inside about an hour, usually easier word retrieval and steadier attention. The clocks separate after that. Semax reaches full effect at 2 weeks with a 2-week window. Noopept was studied in courses of 1.5 to 3 months, so a two-week noopept trial tells you almost nothing about the part that was studied.
- Can I take noopept and semax together?
- There is no good reason to. Both converge on NGF and BDNF signalling by different routes, so the pairing is redundant rather than additive. You would double the gray-market sourcing risk and lose any ability to tell which compound produced a benefit or a side effect. Run one at a time against a marker you wrote down before starting.
- Who should avoid both?
- Anyone pregnant or breastfeeding, and anyone competing in drug-tested sport without formal clearance. Noopept additionally rules out anyone under 18, anyone with severe hepatic or renal impairment, and anyone with hypertension or taking an antihypertensive. Semax additionally rules out seizure history, high baseline anxiety, unstable psychiatric symptoms and MAOI therapy.
- Are they legal to buy?
- Neither is approved in the US, and both are gray market. Noopept has been an over-the-counter medicine in Russia since about 2006 and is an unapproved new drug in the US, named in a 2019 FDA warning letter; sale for human consumption is prohibited in the UK and Hungary controls it. Semax is approved in Russia and sold in the US as a research nasal spray with no product standard.
- Has Nick used either of these?
- Both. Semax was the first nootropic peptide I tried and I still use it several times a month, primarily as a nasal spray, where the effect feels subtle and situational. I rate it 6.5. Noopept I started playing with around 2014, and I rotate it in occasionally with long breaks between runs. I rate it 6.1.
Evidence Sources
- Ostrovskaya et al. 2002, Eksperimental'naia i klinicheskaia farmakologiia: the original novel nootropic and neuroprotective agent noopept Foundational pharmacology from the lab that developed noopept. Reports broader memory-related activity than piracetam in animal models plus anxiolytic and neuroprotective effects. The same institute holds the compound's pharmacology patents.
- Ostrovskaya et al. 2008, Bulletin of Experimental Biology and Medicine: noopept stimulates NGF and BDNF expression in rat hippocampus The most cited noopept mechanism study. Acute dosing raised hippocampal NGF and BDNF messenger RNA in rats, and a 28-day course potentiated the effect rather than producing tolerance. Never reproduced in a human tissue or imaging endpoint.
- Amelin et al. 2011, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova: noopept in mild cognitive impairment after stroke Noopept's strongest human trial. An open prospective study of 60 stroke patients at 20 mg daily for two months reported improved cognitive function and a high level of safety. Open-label, no placebo arm.
- Neznamov and Teleshova 2009, Neuroscience and Behavioral Physiology: noopept against piracetam in mild cognitive disorders of vascular and traumatic origin The second identifiable human trial, unblinded, over 56 days. Secondary sources report 20 mg daily, MMSE movement and blood-pressure rises in a minority, but the full text could not be opened, so those figures are reported rather than confirmed.
- Ostrovskaya et al. 2014, Journal of Biomedical Science: noopept in an Alzheimer-related cellular model PC12 cells under amyloid beta toxicity. Noopept cut reactive oxygen species, calcium overload and tau phosphorylation at serine 396 and restored mitochondrial membrane potential. The clearest neuroprotection evidence noopept has, and it is in a dish.
- Cohen et al. 2020, Neurology Clinical Practice: five unapproved drugs found in cognitive enhancement supplements The purity study for this category. Among products declaring a quantity, 9 of 12 declared amounts were inaccurate, ranging from 0 to 135 percent of label, with possible exposure up to four times pharmaceutical dosing.
- Noopept reduces postischemic functional and metabolic disorders in rat brain, Bulletin of Experimental Biology and Medicine 2009 Rat bilateral carotid ligation model. Seven days of dosing improved survival and behaviour and lowered lipid peroxidation products. The animal study closest to the vascular population the human trials enrolled.
- Cognitive enhancer noopept activates transcription factor HIF-1, Doklady Biochemistry and Biophysics 2020 Neuroblastoma cell study showing increased HIF-1 DNA-binding activity through prolyl hydroxylase inhibition. The mechanism most often invoked to explain noopept's ischemia results.
- Molecular mechanism underlying the action of the substituted pro-glycine dipeptide noopept, Acta Naturae 2016 A transcription-factor screen showing noopept selectively activates HIF-1 and docks to prolyl hydroxylase 2. Corroborates the neuroblastoma work in a different reporter system rather than adding an independent mechanism.
- Noopept action on CA1 pyramidal neurons involves alpha-7 acetylcholine receptors on interneurons, Neuroscience Letters 2022 Slice electrophysiology. Noopept raised inhibitory currents onto CA1 pyramidal neurons through alpha-7 nicotinic receptors, blocked by two selective antagonists. The cholinergic link behind pairing noopept with a choline source.
- Pharmacokinetics of noopept and its active metabolite cycloprolylglycine in rats, Biomeditsinskaia khimiia 2018 The rat study behind the prodrug story. Cycloprolylglycine differs from the parent compound on pharmacokinetic parameters while keeping a similar pharmacological profile. No human study has confirmed the conversion at real doses.
- An experimental study of the anti-inflammatory action of noopept and its effect on cytokine levels, Eksperimental'naia i klinicheskaia farmakologiia 2012 Rodent carrageenan and lipopolysaccharide models. Noopept cut interleukin-6 by roughly 1.8 times and halved tumour necrosis factor alpha against controls. Animal-only, with no human inflammatory marker reported.
- Giurgea 1972, Actual Pharmacol (Paris): an attempt at a nootropic concept in psychopharmacology The paper that named the nootropic category while developing piracetam, the compound noopept was designed to improve on. Conceptual rather than a trial, and the historical starting point for this class.
- FDA warning letter to Peak Nootropics LLC, 2019: unapproved new drugs sold as dietary supplements The regulatory record for noopept's US status. The agency named noopept among unapproved and misbranded drug ingredients sold as supplements, which is why no lawful US retail channel exists.
- Russian instructions for use, Noopept tablets, 2026 translation The only formal dosing document for noopept. It sets 10 mg twice daily with a 30 mg ceiling, courses of 1.5 to 3 months, and contraindicates pregnancy, breastfeeding, age under 18 and severe hepatic or renal impairment.
- Semax in combination with rehabilitation in post-ischemic stroke patients, Zh Nevrol Psikhiatr Im S S Korsakova 110 post-ischemic-stroke patients. Semax plus rehabilitation raised plasma BDNF and improved Barthel and motor-recovery scores. Semax's strongest human anchor, not independently replicated in the West.
- Semax affects BDNF and trkB expression in rat hippocampus, Brain Research BDNF and TrkB upregulation in rat hippocampus after intranasal semax, with a conditioned-learning signal. The mechanistic basis for the semax neuroplasticity score.
- Nootropic analog of adrenocorticotropin 4-10 Semax, Zh Vyssh Nerv Deiat Im I P Pavlova Human attention and operative-memory direction for semax. Numbers were not independently verified during the report audit.
- Effects of Semax on human attention and memory, Neuroscience Research Communications Small human nootropic-like activity signal for semax. Verified by DOI only, with no PMID found.
- Protection of episodic memory by Semax in hypoxic-exposed Sprague Dawley rats, American Journal of Biomedical Science and Research Animal hypoxia and novel-object-recognition memory protection. The basis for reading semax as a stress-resilience candidate without reaching a human endpoint.
- Protective properties of Semax after cerebral ischemia-reperfusion in rats, Genes Preclinical transcriptomic support for the semax neuroprotection mechanism.
- WADA guidance on non-approved substances (S0) Explains the S0 non-approved substance category, which can apply to semax and to noopept even though neither is named directly.
Glossary
Quick reference for the medical and technical terms used in this comparison.
- cPG Cycloprolylglycine
- The cyclic dipeptide noopept converts into, and the molecule most of the mechanism work actually studies. The conversion has been measured in rats, never in people.
- Prodrug Prodrug
- A compound that is inactive or weakly active until the body converts it into something else. Noopept is one; semax is not.
- BDNF Brain-Derived Neurotrophic Factor
- A protein supporting neuron survival, synaptic plasticity, learning and memory. Both compounds aim at it, and Gusev 2018 measured it in stroke patients on semax.
- NGF Nerve Growth Factor
- A neurotrophin involved in neuron survival and repair. Both compounds are described as raising it, noopept in rat hippocampus and semax through its own signalling.
- TrkB Tropomyosin Receptor Kinase B
- The main receptor for BDNF. Dolotov 2006 found both BDNF and TrkB upregulation in rat hippocampus after intranasal semax.
- MMSE Mini-Mental State Examination
- A 30-point cognitive screening test used as the main outcome in both noopept trials. It is a screen rather than a memory battery, so a change in it is a coarse signal.
- Open-label Unblinded Trial
- A trial where patient and doctor both know what is being given, so it cannot separate a drug effect from expectation. Every human trial of either compound is open-label.
- HIF-1 Hypoxia-Inducible Factor 1
- A transcription factor that switches on when oxygen is scarce. Noopept activates it through prolyl hydroxylase inhibition, which is the mechanism invoked for its ischemia results.
- ACTH Adrenocorticotropic Hormone
- Semax is built from the ACTH 4-7 fragment plus a Pro-Gly-Pro tail for stability, not from the full hormone, so it lacks the parent hormone's endocrine action.
- WADA S0 Non-Approved Substances Category
- The anti-doping catch-all covering substances with no current regulatory approval. It can apply to a compound even when it is not named on the list.
